España
CLSN
Se pone a comercializar sus reactivos de reciente adquisición:
TheraPlas™ and TheraSilence™. TheraPlas™ and TheraSilence™ are designed for optimal transfection (intra-cellular delivery) of plasmid DNA and RNA into human (and other mammalian) cells.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
NAVB
Joint venture con Rheumco LLC (noticia de ayer)
http://seekingalpha.com/news/1847945-navidea-forms-jv-to-exploit-unmet-needs-in-the-autoimmune-space
«Después de nada, o después de todo/ supe que todo no era más que nada.»
Y el hecho de pasar de 65 a 41 millones de acciones en corto en apenas seis meses como se entiende? Visto como se ha movido la
cotización en ese tiempo... Raro, raro...
BDPT
Me voy del corto con un +36% y 600 pavos, que no me fío un pelo de que no la reaviven momentáneamente y me olvido de ella. Al final las HEMP no produjeron nada más que quebraderos de cabeza, pero sus dividendos en forma de acciones chicharriles me han compensado con 1500 pavos entre el largo y el corto.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
Pues en teoria dice lo contrario, pero la reduccion de cortos es progresiva desde hace meses. Esta mala pinta de ahora, es de hace unos dias.
ARNA
Espero que con paciencia nos la quitaremos de encima más que dignamente :)
NVAX
Tener en dos semanas el report financiero no ayuda tampoco precisamente.
NVAX
STEM
Hizo hace un par de días dilución del 20%
http://www.marketwatch.com/story/stemcells-inc-announces-proposed-20-million-offering-2014-07-15
Pero hoy sale una noticia a la luz (que parece que aún no ha llegado a los medios) y de la que le va a costar volver a levantar cabeza si se prueba cierta: uno de sus directores denuncia que no se han seguido las buenas prácticas, que se han contaminado las líneas de células y que se ha puesto en peligro a los pacientes. Carne de corto vamos (y vía completamente libre para ACTC). Copio la noticia a continuación. Edito: ahora que lo pienso, este tipo de noticias se la suelen sudar a Wall-Street a corto plazo, así que retiro mi idea de corto, pero a la larga la empresa se irá a la mierda si tiene las líneas contaminadas, porque les tumbarán los ensayos.
Por su parte, ISCO, tras su dilución parece que toma un buen rumbo con la ampliación de la distribución de sus productos
http://finance.yahoo.com/news/lifeline-cell-technology-expands-asian-123000147.html
y, sobre todo, con la **posible** decisión positiva (aún por ver) del Tribunal Europeo de poder patentar su tipo de células embrionarias:
http://online.wsj.com/articles/eu-court-adviser-backs-stem-cell-patenting-1405592870?mod=yahoo_hs
http://online.wsj.com/articles/eu-court-adviser-backs-stem-cell-patenting-1405592870?mod=yahoo_hs
StemCells Inc. Problems?
Whistle-Blower Alarmed at Stem Cell Work
By ELIZABETH WARMERDAM
Wednesday, July 16, 2014 Last Update: 7:43 AM PT
OAKLAND, Calif. (CN) - A stem cell research company fired a manager after he complained that deficiencies in the company's cell lines put patients at risk of infection or death during clinical trials, the man claims in court.
Rob Williams sued StemCells Inc. on Monday in Alameda County Court, alleging wrongful termination, retaliation and violation of the California False Claims Act.
To receive millions of dollars in government funding, including grants from the California Institute for Regenerative Medicine, StemCells claims that its manufacturing processes yield stem cells that are "safe for human stem cell transplantation," the complaint states.
StemCells must follow a set of standards - Good Manufacturing Practices - set forth by the FDA to protect the public, according to the complaint.
Williams says he was hired as the company's senior manager of manufacturing in December 2013 to oversee its manufacturing facility, where stem cell cultures are cultivated for use in clinical trials.
"Shortly after beginning his employment, plaintiff noted poor sterile technique, failure to adhere to current Good Manufacturing Practices in the company's manufacturing process, and substantial deficiencies in the company's Manual Aseptic Processing of HuCNS-SC (Human Central Nervous System Stem Cells) cell lines - failure and deficiencies that put patients at risk of infection or death during ongoing clinical trials," Williams says.
Williams claims he also saw manufacturing deviations during cryopreservation of Working Cell Bank lots, leading to numerous stem cell lots with dangerously high numbers of damaged cells.
"Knowing that these cells were to be injected into human patients, and that the high level of damaged cells and the possibility of contaminating microorganisms could cause serious harm to patients, plaintiff immediately took his concerns to upper management. He also noted that the use of adulterated stem cells lots could skew patient test results, effectively jeopardizing data behind years of clinical trials and research," the complaint states.
Williams says he was told to conceal his findings from reports, and the company suspended him shortly thereafter.
Williams sent emails to company leadership and members of the company's executive team reiterating his concerns about the processes used to create the stem cell lines for use in human patients. He also described the suspension he faced as retaliation for bringing the issue out into the open, the complaint states.
StemCells fired Williams a few weeks later, he says.
Williams seeks punitive damages.
He is represented by Daniel Velton with Velton Zegelman, of Sunnyvale.
StemCells did not immediately respond to a request for comment.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
